Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma

Ann Oncol. 1991 May;2(5):377-8. doi: 10.1093/oxfordjournals.annonc.a057960.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / etiology
  • Brain Neoplasms / secondary
  • Drug Evaluation
  • Europe
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Middle Aged
  • Nitrosourea Compounds / therapeutic use*
  • Nitrosourea Compounds / toxicity
  • Organophosphorus Compounds / therapeutic use*
  • Organophosphorus Compounds / toxicity
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Nitrosourea Compounds
  • Organophosphorus Compounds
  • fotemustine